The effect of LIGHT in inducing maturation of monocyte-derived dendritic cells from MDS patients

被引:28
作者
Zou, GM
Martinson, J
Hu, WY
Tam, Y
Klingemann, HG
机构
[1] Inex Pharmaceut, Vancouver, BC, Canada
[2] Rush Univ, Med Ctr, Bone Marrow Transplantat Sect, Chicago, IL 60612 USA
关键词
CD40L; dendritic cells; LIGHT; MDS; monocytes;
D O I
10.1007/s00262-004-0518-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LIGHT is a recently cloned novel cytokine belonging to the TNF family that is selectively expressed on immature dendritic cells (iDCs) generated from monocytes isolated from human PBMCs. In these studies, we demonstrate that exogenous soluble LIGHT or soluble CD40 ligand (CD40L) can promote monocyte-derived dendritic cell maturation in vitro by the up-regulation of CD86, CD80, CD83, and HLA-DR antigen expression. Immature dendritic cells differentiated from monocytes of MDS patients displayed lower levels of costimulatory and HLA-DR molecules compared with iDCs differentiated from monocytes of normal subjects. However, upon induction of maturation by LIGHT or CD40L, the expression of costimulatory and HLA-DR molecules is comparable between DCs from MDS and normal subjects. Exogenous LIGHT- and CD40L-stimulated mature DCs (mDCs) also displayed increased antigen presentation to autologous T lymphocytes (tetanus toxin) or allogeneic T lymphocytes in mixed lymphocyte reactions. DCs matured by LIGHT showed increased secretion of IL-6, IL-12p75, and TNF-alpha, but not IL-1beta. We conclude that both LIGHT and CD40L are immunoregulating factors that induce monocyte-derived iDCs from MDS patients to undergo maturation resulting in increased antigen presentation and T-cell activation. Monocyte-derived DCs can be stimulated to undergo phenotypic and functional changes with LIGHT that might be applied in the development of a DC-based vaccine for MDS treatment.
引用
收藏
页码:681 / 689
页数:9
相关论文
共 38 条
[1]   Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors [J].
Ashley, DM ;
Faiola, B ;
Nair, S ;
Hale, LP ;
Bigner, DD ;
Gilboa, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1177-1182
[2]   DENDRITIC CELLS INITIATE A 2-STAGE MECHANISM FOR LYMPHOCYTE-T PROLIFERATION [J].
AUSTYN, JM ;
STEINMAN, RM ;
WEINSTEIN, DE ;
GRANELLIPIPERNO, A ;
PALLADINO, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 157 (04) :1101-1115
[3]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[4]   Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10 [J].
Brown, RD ;
Pope, B ;
Murray, A ;
Esdale, W ;
Sze, DM ;
Gibson, J ;
Ho, PJ ;
Hart, D ;
Joshua, D .
BLOOD, 2001, 98 (10) :2992-2998
[5]   GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS [J].
CAUX, C ;
DEZUTTERDAMBUYANT, C ;
SCHMITT, D ;
BANCHEREAU, J .
NATURE, 1992, 360 (6401) :258-261
[6]   Origin, maturation and antigen presenting function of dendritic cells [J].
Cella, M ;
Sallusto, F ;
Lanzavecchia, A .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :10-16
[7]   Differentiation of human dendritic cells from monocytes in vitro [J].
Chapuis, F ;
Rosenzwajg, M ;
Yagello, M ;
Ekman, M ;
Biberfeld, P ;
Gluckman, JC .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (02) :431-441
[8]   The role of tumor necrosis factor α in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro [J].
Chen, BG ;
Shi, YJ ;
Smith, JD ;
Choi, D ;
Geiger, JD ;
Mulé, JJ .
BLOOD, 1998, 91 (12) :4652-4661
[9]   Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy [J].
Fong, L ;
Brockstedt, D ;
Benike, C ;
Breen, JK ;
Strang, G ;
Ruegg, CL ;
Engleman, EG .
JOURNAL OF IMMUNOLOGY, 2001, 167 (12) :7150-7156
[10]   Severe and selective deficiency of interferon-γ-producing invariant natural killer T cells in patients with myelodysplastic syndromes [J].
Fujii, S ;
Shimizu, K ;
Klimek, V ;
Geller, MD ;
Nimer, SD ;
Dhodapkar, MV .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) :617-622